Table 1.
Demographic characteristics in cohort and The European Surveillance System data for individuals diagnosed between 2000 and 2013, Germany, Greece and the United Kingdom; for France, only individuals diagnosed between 2003 and 2013 were included and for Italy only data for 2010–2013, whereas in Spain only individuals diagnosed between 2005 and 2013 are included.
| France | Germany | Greece | Italy | Spain | United Kingdom | |||||||
| Cohort, N = 28 758 | Surveillance, N = 59 480 | Cohort, N = 14 146 | Surveillance, N = 33 845 | Cohort, N = 6217 | Surveillance, N = 8475 | Cohort, N = 3303 | Surveillance, N = 15 449 | Cohort, N = 8374 | Surveillance, N = 28 113 | Cohort, N = 35 970 | Surveillance, N = 90 075 | |
| N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | |
| Transmission mode | ||||||||||||
| MSM | 11 067 (38.5) | 20 238 (34.0) | 8206 (58.0) | 21 730 (64.2) | 3776 (60.7) | 4535 (53.5) | 1637 (49.6) | 6252 (40.5) | 5239 (62.6) | 14 980 (53.3) | 17 560 (48.8) | 36 019 (40.0) |
| PWID | 577 (2.0) | 2305 (3.9) | 948 (6.7) | 2019 (6.0) | 759 (12.2) | 1482 (17.5) | 201 (6.1) | 947 (6.1) | 497 (5.9) | 2521 (9.0) | 724 (2.0) | 2168 (2.4) |
| Other | 17 114 (59.5) | 36 937 (62.1) | 4992 (35.3) | 10 096 (29.8) | 1682 (27.1) | 2458 (29.0) | 1465 (44.4) | 8250 (53.4) | 2638 (31.5) | 10 612 (37.7) | 17 686 (49.2) | 51 888 (57.6) |
| Sex | ||||||||||||
| Male | 19 091 (66.4) | 38 144 (64.1) | 11 191 (79.1) | 27 691 (81.8) | 5287 (85.0) | 6988 (82.5) | 2658 (80.5) | 11 898 (77.0) | 7054 (84.2) | 22 904 (81.5) | 24 761 (68.8) | 57 562 (63.9) |
| Female | 9667 (33.6) | 21 336 (35.9) | 2955 (20.9) | 6154 (18.2) | 930 (15.0) | 1487 (17.5) | 645 (19.5) | 3551 (23.0) | 1320 (15.8) | 5209 (18.5) | 11 209 (31.2) | 32 513 (36.1) |
| Age group | ||||||||||||
| 15–24.9 | 3316 (11.5) | 5543 (9.3) | 1671 (11.8) | 3953 (11.7) | 731 (11.8) | 788 (9.3) | 367 (11.1) | 1278 (8.3) | 1088 (13.0) | 3083 (11.0) | 4525 (12.6) | 10 156 (11.3) |
| 25–34.9 | 10 109 (35.2) | 18 632 (31.3) | 4476 (31.6) | 11 614 (34.3) | 2571 (41.4) | 3297 (38.9) | 1076 (32.6) | 4748 (30.7) | 3343 (39.9) | 10 322 (36.7) | 14 630 (40.7) | 34 521 (38.3) |
| 35–44.9 | 8639 (30.0) | 18 762 (31.5) | 4777 (33.8) | 10 681 (31.6) | 1720 (27.7) | 2457 (29.0) | 1030 (31.2) | 4909 (31.8) | 2486 (29.7) | 8864 (31.5) | 11 066 (30.8) | 28 334 (31.5) |
| 45–54.9 | 4346 (15.1) | 10 613 (17.8) | 2098 (14.8) | 5074 (15.0) | 761 (12.2) | 1148 (13.5) | 570 (17.3) | 2935 (19.0) | 1026 (12.3) | 4039 (14.4) | 4187 (11.6) | 11 916 (13.2) |
| 55+ | 2348 (8.2) | 5930 (10.0) | 1124 (7.9) | 2523 (7.5) | 434 (7.0) | 785 (9.3) | 260 (7.9) | 1579 (10.2) | 431 (5.1) | 1805 (6.4) | 1562 (4.3) | 5148 (5.7) |
| Origin | ||||||||||||
| Reporting country | 18 889 (65.7) | 29 138 (49.0) | 9575 (67.7) | 18 039 (53.3) | 5228 (84.1) | 6572 (77.5) | 2751 (83.3) | 12 389 (80.2) | 5538 (66.1) | 17 489 (62.2) | ||
| Europe, USA | 731 (2.5) | 2576 (4.3) | 1595 (11.3) | 2619 (7.7) | 413 (6.6) | 926 (10.9) | 552 (16.7) | 3060 (19.8) | 481 (5.7) | 2115 (7.5) | ||
| Africa, Asia, etc | 9138 (31.8) | 27 766 (46.7) | 2976 (21.0) | 13 187 (39.0) | 576 (9.3) | 977 (11.5) | 2355 (28.1) | 8509 (30.3) | ||||
| CD4+ cells/μla | ||||||||||||
| <200 | 1309 (23.5) | 6186 (30.3) | 1702 (27.4) | 2948 (34.8) | 881 (26.7) | 5651 (36.6) | 1932 (23.1) | 8266 (29.4) | 9525 (26.5) | 28 956 (32.1) | ||
| 200–349 | 1291 (23.1) | 4433 (21.7) | 1353 (21.8) | 1901 (22.4) | 636 (19.3) | 3093 (20.0) | 1661 (19.8) | 5430 (19.3) | 8346 (23.2) | 20 646 (22.9) | ||
| 350–499 | 1198 (21.5) | 3804 (18.7) | 1191 (19.2) | 1399 (16.5) | 666 (20.2) | 2661 (17.2) | 1743 (20.8) | 5173 (18.4) | 7519 (20.9) | 17 113 (19.0) | ||
| 500+ | 1785 (32.0) | 5968 (29.3) | 1971 (31.7) | 2227 (26.3) | 1120 (33.9) | 4044 (26.2) | 3038 (36.3) | 9244 (32.9) | 10 580 (29.4) | 23 360 (25.9) | ||
PWID, people who inject drug.
aFor France CD4+ cell counts concern only on the last study period (2008–2013).